H.C. Wainwright Initiates Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $80

Futu NewsDec 21 02:31 · Ratings

Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Prothena (PRTA) and CVS Health (CVS)

TipRanksDec 21 02:07 · Ratings

Promising Potential of Structure Therapeutics' ACCG-2671 Drives Buy Rating

TipRanksDec 21 02:00 · Ratings

Buy Rating for Structure Therapeutics, Inc. Driven by Innovative Drug Development and Promising Obesity Treatment Platform

TipRanksDec 21 01:45 · Ratings

Express News | Shares of Viking Therapeutics up 4.2%, Amgen up 1%

BreakingsDec 20 22:34

The weight loss effect of the new drug was below expectations, and Novo-Nordisk A/S saw its stock plummet by 28% in Pre-Market Trading, while competitor Eli Lilly and Co surged over 12%.

The experimental results show that patients who received subcutaneous injections of CagriSema lost an average of 22.7% of their weight after 68 weeks. If volunteers who dropped out of the trial are included, the average weight loss effect decreases to 20.4%, both below the company's previous expectation of 25%.

wallstreetcnDec 20 19:49